+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 100Years
All Genders
ID06766071

Evaluating Pharmacogenomics and Adverse Drug Reactions in Patients Taking Multiple Medications Using Whole Genome Sequencing and Clinical Decision Support Tools

Led by Texas A&M University · Updated on 2026-09-30

50

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety issues linked to taking many medications at once, called polypharmacy, especially focusing on adverse drug reactions ADRs in patients using advanced pharmacogenomic technology. The study aims to improve medication plans by creating a customized electronic dashboard that helps identify medications to adjust or stop. It also assesses how well certain liver enzymes work in these patients and tests the feasibility of integrating whole genome sequencing data with electronic health records and clinical workflows. Participants medication regimens will be examined using pharmacogenomic tests including genotyping and research-use-only whole genome sequencing. The study uses an interprofessional care model involving physicians, pharmacists, nurses, and digital tools like telemedicine to gather detailed patient data, including genetic, functional, and social factors. This data supports a clinical decision system designed to optimize medication management and reduce risks from drug interactions. The pilot phase focuses on evaluating the capacity of liver enzymes and refining informatics workflows between labs, electronic medical records, and primary care. Throughout the study, participants provide genetic samples, urine, and blood and undergo physical exams and comprehensive histories. Researchers monitor adverse drug reactions and emergency department visits over 180 days, using questionnaires and clinical data collection. The study observes how pharmacogenomic information can guide safer and more precise medication management in patients taking multiple drugs. Participation lasts up to the study completion date in January 2029, with data helping to develop future precision medicine tools.

CONDITIONS

Brief Title

IPGx PILOT Whole Genome Sequencing Extension Cohort

Research Team

K

Kenneth S Ramos,, MD

R

Rick Silva, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here